Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Surgery, University of Miami, Miami, FL, USA.
HPB (Oxford). 2018 Dec;20(12):1150-1156. doi: 10.1016/j.hpb.2018.05.011. Epub 2018 Jul 11.
In patients with stage IV colorectal cancer (CRC), minimally invasive surgery (MIS) may offer optimal oncologic outcome with low morbidity. However, the relative benefit of MIS compared to open surgery in patients requiring multistage resections has not been evaluated.
Patients who underwent totally minimally invasive (TMI) or totally open (TO) resections of CRC primary and liver metastases (CLM) in 2009-2016 were analyzed. Inverse probability of weighted adjustment by propensity score was performed before analyzing risk factors for complications and survival.
The study included 43 TMI and 121 TO patients. Before and after adjustment, TMI patients had significantly less cumulated postoperative complications (41% vs. 59%, p = 0.001), blood loss (median 100 vs. 200 ml, p = 0.001) and shorter length of hospital stay (median 4.5 vs. 6.0 days, p < 0.001). Multivariate analysis identified TO approach vs. MIS (OR = 2.4, p < 0.001), major liver resection (OR = 4.4, p < 0.001), and multiple CLM (OR = 2.3, p = 0.001) as independent risk factors for complications. 5-year overall survival was comparable (81% vs 68%, p = 0.59).
In patients with CRC undergoing multistage surgical treatment, MIS resection contributes to optimal perioperative outcomes without compromise in oncologic outcomes.
在患有 IV 期结直肠癌(CRC)的患者中,微创外科(MIS)可能提供最佳的肿瘤学结果,同时发病率较低。然而,在需要多阶段切除的患者中,MIS 与开放手术相比的相对益处尚未得到评估。
分析了 2009 年至 2016 年间接受完全微创(TMI)或完全开放(TO)结直肠原发灶和肝转移瘤(CLM)切除术的患者。在分析并发症和生存的危险因素之前,通过倾向评分进行了逆概率加权调整。
本研究纳入了 43 例 TMI 和 121 例 TO 患者。在调整前后,TMI 患者的累积术后并发症发生率(41%比 59%,p = 0.001)、出血量(中位数 100 比 200 ml,p = 0.001)和住院时间(中位数 4.5 比 6.0 天,p < 0.001)均显著减少。多变量分析确定了 TO 方法与 MIS(OR = 2.4,p < 0.001)、主要肝切除术(OR = 4.4,p < 0.001)和多个 CLM(OR = 2.3,p = 0.001)是并发症的独立危险因素。5 年总生存率相当(81%比 68%,p = 0.59)。
在接受多阶段手术治疗的 CRC 患者中,MIS 切除有助于实现最佳的围手术期结果,而不会影响肿瘤学结果。